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Balanced calcitriol treatment  
to make children grow
E Neven1, V Persy1 and PC D’Haese1
Short stature is an important clinical problem in children with  
chronic kidney disease. Calcitriol is used as standard therapy to 
control secondary hyperparathyroidism, but its effect on linear 
growth remains controversial. Sanchez and He report multiple  
effects of calcitriol on chondrocyte proliferation and maturation  
that might help to clarify this controversy.
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Growth impairment is a major problem 
in children suﬀering from chronic kidney 
disease (CKD). The North American Pedi-
atric Renal Trials and Collaborative Stud-
ies reports that at the time of entry to the 
registry, 37% of children with CKD have 
severe linear growth delay, deﬁned as body 
length below the third percentile for age.1 
Linear growth of long bones is achieved 
by endochondral bone formation. A car-
tilaginous precursor template is produced 
by chondrocytes, which go through a coor-
dinated program of proliferation, matura-
tion, and hypertrophic diﬀerentiation, in 
the growth plate. As chondrocytes become 
hypertrophic, they undergo apoptosis and 
hereby initiate cartilage matrix minerali-
zation. After vascular invasion, by which 
osteoblasts and osteoclasts are supplied 
to the growth plate, the cartilage matrix is 
replaced by bone.
In addition to protein malnutrition, 
metabolic acidosis, and anemia, both 
growth hormone resistance and renal 
osteodystrophy are important, recognized 
factors contributing to growth retardation 
in these young patients. Accordingly, in 
order to improve bone growth, patients are 
treated with recombinant human growth 
hormone and/or 1,25-dihydroxyvitamin 
D3 (calcitriol, 1,25(OH)2D3), which is 
administered in the ﬁrst place to prevent 
secondary hyperparathyroidism and the 
accompanying high bone turnover. Several 
studies showed that recombinant human 
growth hormone exerts a positive eﬀect 
on chondrocyte proliferation in vitro and 
on longitudinal bone growth in uremic 
rats and children with CKD. On the other 
hand, the eﬀect of calcitriol on bone growth 
seems to be far more complex. The results 
of experimental as well as clinical studies, 
investigating the eﬀect of calcitriol therapy 
and the way it is administered (daily ver-
sus intermittently) on long bone growth 
in uremia, are not unequivocal. Daily, but 
not intermittent, calcitriol therapy has been 
shown to increase bone growth in uremic 
rats2 and children3 with CKD, whereas 
other studies revealed that both treatment 
strategies are equally eﬀective in growth 
improvement.4 Contrary to these observa-
tions, the development of low bone turno-
ver and the subsequent failure in growth 
enhancement has also been reported in 
calcitriol-treated CKD patients.5
Sanchez and He6 (this issue) investigated 
this controversy by comparing the eﬀect 
of daily and intermittent calcitriol therapy 
on the expression of chondrocyte prolif-
eration and diﬀerentiation markers in the 
growth plates of 5/6 nephrectomized rats 
(Figure 1). Because longitudinal bone 
growth results mainly from endochondral 
bone formation, it is interesting to study the 
molecular alterations in the proliferative 
and hypertrophic zone of the epiphyseal 
growth plate under calcitriol treatment 
in addition to changes in body and tibial 
length as outcome parameters. Daily as 
well as intermittent calcitriol administra-
tion resulted in an increased expression of 
proliferation and diﬀerentiation markers 
in growth plate chondrocytes, but also in 
an increased expression of proliferation 
inhibitors, probably explaining why nei-
ther calcitriol dosing regimen improved 
the impaired body and tibial growth in 
uremic rats, as discussed by the authors.6
Both parathyroid hormone (PTH) and 
1,25(OH)2D3, two factors regulating each 
other’s production in the parathyroid 
gland and the kidney, respectively, can 
play a regulatory role in bone growth. In 
the setting of CKD, the regulation of these 
hormones is seriously disturbed. Severe 
secondary hyperparathyroidism in CKD, 
characterized by a high bone turnover and 
often accompanied by an impaired miner-
alization and the presence of bone marrow 
ﬁbrosis, can ultimately aﬀect bone growth. 
In addition, the 1,25(OH)2D3 deﬁciency 
due to the impaired renal function can 
also contribute to the reduced growth in 
pediatric CKD patients.
However, despite the harmful eﬀects of 
excessive serum PTH concentrations on 
bone turnover, this hormone, when present 
in its normal concentration range, tightly 
regulates bone metabolism, including bone 
growth. The stimulating eﬀect of PTH on 
endochondral bone formation is demon-
strated by an increased long bone length, 
increased epiphyseal volume, and upregu-
lated chondrocyte proliferation and dif-
ferentiation, as well as an increased matrix 
mineralization, in 25-hydroxyvitamin D-
1α-hydroxylase and PTH double-knock-
out mice treated with PTH for 10 days.7 In 
vitro experiments showed that incubation 
of rabbit chondrocytes with PTH inhibited 
the terminal diﬀerentiation toward hyper-
trophic chondrocytes.8 The ﬁnding that the 
PTH/PTHrP receptor is mainly expressed 
in the lower proliferative and the matrix-
forming zone (upper hypertrophic zone) 
is consistent with the proliferative eﬀect 
of PTH on growth plate chondrocytes. 
However, Xue et al.9 recently found that 
PTH deﬁciency resulted in only a slight 
decrease in longitudinal bone length, but 
a signiﬁcant reduction in trabecular bone 
volume. In contrast, 25-hydroxyvitamin 
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Figure 1 | Expression of proliferation, differentiation, and osteoclastogenesis markers and 
proliferation inhibitors in the different zones of the growth plate in uremic rats, reported 
by Sanchez et al.6 Both daily and intermittent calcitriol enhanced chondrocyte proliferation 
and maturation. In addition, the expression of the proliferation inhibitors p57Kip and p21Cip/Waf 
was also upregulated under calcitriol treatment. The upregulation of both - proliferation markers 
and proliferation inhibitors may explain why calcitriol administration did not increase bone 
growth in uremic rats. mTOR, mammalian target of rapamycin; IGFBP-3, insulin-like growth factor-
binding protein-3; CaR, calcium receptor; FGFR3, fibroblast growth factor receptor 3; BMP-7, bone 
morphogenetic protein-7; IGF-1, insulin-like growth factor-1; VDR, vitamin D receptor; FGF-23, 
fibroblast growth factor-23; RANKL, receptor activator of NF-KB ligand; OPG, osteoprotegerin.
with an upregulation of proliferation 
inhibitors in growth plate chondrocytes of 
uremic rats treated with daily or intermit-
tent calcitriol, supports the idea that the 
balance between proliferative and antipro-
liferative eﬀects can modify the net eﬀect 
on endochondral bone growth and that 
this balance can turn over in either direc-
tion depending on substantial diﬀerences 
in calcitriol concentration.
Impaired growth leading to small adult 
stature has been demonstrated to aﬀect psy-
chosocial well-being and quality of life, as 
well as to entail increased mortality risk in 
children with CKD.11 The disturbances in 
the growth hormone–insulin-like growth 
factor-1 axis that is one of the etiological 
factors in growth retardation accompany-
ing CKD can be treated with recombinant 
human growth hormone, which has been 
shown to eﬀectively improve growth and 
adult height in these patients. However, in 
case of uncontrolled hyperparathyroidism 
and renal osteodystrophy, growth hor-
mone therapy is contraindicated. Moreo-
ver, increased PTH levels and calcitriol 
deficiency also negatively affect bone 
growth, in a way that is still incompletely 
understood. The results presented by 
Sanchez and He6 illustrate the complex 
regulation of endochondral bone forma-
tion process by calcitriol and put in per-
spective the diﬃcult exercise clinicians are 
confronted with in young CKD patients, 
when trying to ﬁnd the optimal balance 
between adequate treatment of secondary 
hyperparathyroidism on the one hand and 
the risk of PTH oversuppression leading to 
adynamic bone disease on the other hand. 
Therefore, the evaluation and validation of 
new markers in addition to PTH to assess 
and follow up bone status in these patients, 
together with studies investigating whether 
calcitriol analogues or calcimimetics can 
facilitate achievement of this delicate bal-
ance necessary to maintain bone growth, 
are of particular interest.
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D-1α-hydroxylase knockout mice exhibit 
a smaller reduction in trabecular bone 
volume, but a significant decrease in 
bone length. These ﬁndings suggest that 
1,25(OH)2D3 plays a more decisive role in 
endochondral bone formation, and thus 
bone growth, compared with PTH. Fur-
thermore, it has been demonstrated that 
1,25(OH)2D3 regulates chondrocyte pro-
liferation and diﬀerentiation in vitro.
As shown by experimental and clinical 
studies, calcitriol can exert both positive 
and negative eﬀects on longitudinal bone 
growth in uremic subjects. This contro-
versy may be due to diﬀerent administered 
doses of calcitriol used in experiments and 
the remaining endogenous 1,25(OH)2D3 
production, which in turn depends on the 
degree of renal failure. The signiﬁcance of 
the calcitriol dose for its eﬀect is demon-
strated in cell culture experiments: a high 
calcitriol concentration in the medium 
inhibits cell proliferation, whereas a low 
concentration has a stimulatory eﬀect.10 In 
this view, the observation of an increased 
expression of proliferation markers, along 
